Plain-English translation of NCT06853951 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
Children with acute leukemia receive chemotherapy that can sometimes damage the heart muscle over time. This study is testing whether taking or β-blockers — two types of heart-protective medications — alongside chemotherapy can prevent or reduce that damage. The researchers will measure how well the heart is pumping before treatment starts and again after the first phase of chemotherapy ends.
Chemotherapy saves lives, but it can weaken the heart as a side effect. Doctors want to know if starting this medication early and protecting the heart from the beginning of treatment can prevent these problems from developing.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to take either an ACE inhibitor or a β-blocker by mouth — given to you by a parent, guardian, or nurse — alongside your regular leukemia chemotherapy. The study focuses on the induction phase, which lasts about 42 days. Your heart will be checked with an ultrasound at the start and again at the end of this phase to see if the medication helped protect it.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
Egypt
Large-scale testing
Sponsor
Ain Shams University
Enrollment target
~30 participants
Started
July 2023
Primary completion
March 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
1 Year – 18 Years
Last updated on clinicaltrials.gov in March 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Christen Said
Ain Shams University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.